SCHEDULE 13D/A: Major Investor Group Reduces Stake in Repare Therapeutics Through Open Market Sales
Beneficial Ownership Update
An investment group led by MPM BioImpact LLC and its affiliates, including managing directors Ansbert Gadicke, Luke Evnin, and Todd Foley, has significantly reduced its beneficial ownership in Repare Therapeutics Inc. through a series of open market share sales in January 2025.
Summary
- This Schedule 13D/A (Amendment No. 6) reports open market sales of Common Shares of Repare Therapeutics Inc. by a group of affiliated entities and individuals, including MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, UBS Oncology Impact Fund L.P., and their managing directors Ansbert Gadicke, Luke Evnin, and Todd Foley.
- The filing updates previous Schedule 13D statements, with the latest amendment reflecting transactions that occurred between January 6, 2025, and January 15, 2025.
- A total of 509,117 Common Shares were sold across seven trading days in January 2025, with average sale prices ranging from $1.29 to $1.44 per share.
- Following these sales, Ansbert Gadicke's aggregate beneficial ownership stands at 2,149,415 shares, representing 5.1% of the Issuer's Common Shares outstanding.
- Other reporting persons' beneficial ownership percentages are: MPM BioVentures 2014, L.P. at 2.7% (1,127,549 shares), MPM BioVentures 2014 (B), L.P. at 0.2% (75,206 shares), MPM Asset Management Investors BV2014 LLC at 0.1% (38,809 shares), and UBS Oncology Impact Fund L.P. at 2.1% (907,851 shares).
- The calculation of beneficial ownership percentages is based on 42,510,708 Common Shares outstanding as of November 1, 2024, as reported in Repare Therapeutics Inc.'s Form 10-Q filed on November 7, 2024.
Sentiment
Score: 3
Explanation: The sentiment is negative due to significant open market sales by a major investor group and its associated individuals, which typically signals a reduction in confidence or a strategic divestment. This could exert downward pressure on the stock price.
Negatives
- A significant reduction in beneficial ownership by a major institutional investor group and its managing directors, which could be interpreted by the market as a decrease in confidence in the company's future prospects.
- The sales occurred over multiple days, indicating a systematic reduction of exposure rather than a one-off event.
Risks
- The reported open market sales by a significant shareholder group may lead to negative market sentiment and potential downward pressure on Repare Therapeutics Inc.'s share price.
- Investor confidence could be impacted by the divestment of shares by entities and individuals closely associated with the company's early-stage funding and governance.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction; it is solely a report of past share transactions.
Industry Context
This filing is specific to an ownership change within Repare Therapeutics Inc. and does not provide broader industry trends or competitive analysis. However, significant divestments by major biotech investors can sometimes reflect broader shifts in investment strategy within the life sciences sector.
Related Party Transactions
- The sales were conducted by entities (MPM BioVentures funds, UBS Oncology Impact Fund) and individuals (Ansbert Gadicke, Luke Evnin, Todd Foley) who are closely related through their roles as managing directors or partners of the general partners and managing members of these investment vehicles. This indicates a coordinated reduction in stake by a group with significant influence and insight into the company.
Stakeholder Impact
- Shareholders: May perceive the sales as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
- Company Management: Could face questions regarding the reasons for the significant divestment by a key investor group.
Key Dates
| Date | Description |
|---|---|
| 2020-07-06 | Initial Schedule 13D filing date. |
| 2021-03-23 | Amendment No. 1 filed. |
| 2021-05-25 | Amendment No. 2 filed. |
| 2021-07-21 | Amendment No. 3 filed. |
| 2024-11-01 | Date as of which 42,510,708 Common Shares were outstanding, as reported in the Issuer's Form 10-Q. |
| 2024-11-07 | Date of Issuer's Form 10-Q filing with the SEC. |
| 2024-12-26 | Amendment No. 4 filed. |
| 2025-01-06 | Amendment No. 5 filed; first date of reported open market sales. |
| 2025-01-07 | Date of open market sales. |
| 2025-01-08 | Date of open market sales. |
| 2025-01-10 | Date of open market sales. |
| 2025-01-13 | Date of event which requires filing of this statement; date of open market sales. |
| 2025-01-14 | Date of open market sales. |
| 2025-01-15 | Date of open market sales; date of signing of the Schedule 13D/A. |
Recommendation
holdKeywords
SEC filing, Schedule 13D, beneficial ownership, share sales, institutional investor, Repare Therapeutics, biotechnology, MPM BioImpact, Ansbert Gadicke, Luke Evnin, Todd Foley
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.